🇺🇸 FDA
Pipeline program

ARD-101

AARD-203

Phase 2 small_molecule completed

Quick answer

ARD-101 for Prader-Willi Syndrome is a Phase 2 program (small_molecule) at Aardvark Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aardvark Therapeutics
Indication
Prader-Willi Syndrome
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials